Breast cancer in postmenopausal women is associated with an altered gut metagenome

• Published in: Microbiome 2018-08, Vol.6 (1), p.136-13, Article 136
• Main Authors: Zhu, Jia, Liao, Ming, Yao, Ziting, Liang, Wenying, Li, Qibin, Liu, Jianlun, Yang, Huawei, Ji, Yinan, Wei, Wei, Tan, Aihua, Liang, Siyuan, Chen, Yang, Lin, Haisong, Zhu, Xiujuan, Huang, Shengzhu, Tian, Jiarong, Tang, Ruiqiang, Wang, Qiuyan, Mo, Zengnan
• Format: Article
• Language: English
• Subjects: 17β-Estradiol; Actinomyces; Adult; Bacteria - classification; Bacteria - genetics; Bacterial Proteins - genetics; Breast cancer; Breast Neoplasms - metabolism; Breast Neoplasms - microbiology; C-reactive protein; C-Reactive Protein - metabolism; Cancer therapies; Case-Control Studies; CD3 antigen; CD8 antigen; Colorectal cancer; Diabetes; Disease; E coli; Enterococcus gallinarum; Erwinia amylovora; Estradiol - metabolism; Estrogens; Feces; Female; Gastrointestinal Microbiome; Gene expression; Gene Regulatory Networks; Gut microbiota; Health risk assessment; Hormone replacement therapy; Hospitals; Humans; Immunity; Intestinal microflora; Lipopolysaccharides; Liver cirrhosis; Lymphocytes T; Metabolism; Metabolites; Metagenomic analyses; Metagenomics - methods; Microbiota; Microorganisms; Middle Aged; Oxidation; Pathogenesis; Patients; Phylogeny; Post-menopause; Postmenopause - metabolism; Premenopause - metabolism; Shewanella putrefaciens; Species; Studies; Womens health
• ISSN: 2049-2618; 2049-2618
• DOI: 10.1186/s40168-018-0515-3

Increasing evidence suggests that gut microbiota play a role in the pathogenesis of breast cancer. The composition and functional capacity of gut microbiota associated with breast cancer have not been studied systematically. We performed a comprehensive shotgun metagenomic analysis of 18 premenopausal breast cancer patients, 25 premenopausal healthy controls, 44 postmenopausal breast cancer patients, and 46 postmenopausal healthy controls. Microbial diversity was higher in breast cancer patients than in controls. Relative species abundance in gut microbiota did not differ significantly between premenopausal breast cancer patients and premenopausal controls. In contrast, relative abundance of 45 species differed significantly between postmenopausal patients and postmenopausal controls: 38 species were enriched in postmenopausal patients, including Escherichia coli, Klebsiella sp_1_1_55, Prevotella amnii, Enterococcus gallinarum, Actinomyces sp. HPA0247, Shewanella putrefaciens, and Erwinia amylovora, and 7 species were less abundant in postmenopausal patients, including Eubacterium eligens and Lactobacillus vaginalis. Acinetobacter radioresistens and Enterococcus gallinarum were positively but weakly associated with expression of high-sensitivity C-reactive protein; Shewanella putrefaciens and Erwinia amylovora were positively but weakly associated with estradiol levels. Actinomyces sp. HPA0247 negatively but weakly correlated with CD3 CD8 T cell numbers. Further characterization of metagenome functional capacity indicated that the gut metagenomes of postmenopausal breast cancer patients were enriched in genes encoding lipopolysaccharide biosynthesis, iron complex transport system, PTS system, secretion system, and beta-oxidation. The composition and functions of the gut microbial community differ between postmenopausal breast cancer patients and healthy controls. The gut microbiota may regulate or respond to host immunity and metabolic balance. Thus, while cause and effect cannot be determined, there is a reproducible change in the microbiota of treatment-naive patients relative to matched controls.